A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β3 Integrin

Trial Profile

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β3 Integrin

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Focal segmental glomerulosclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Mar 2018.
    • 21 Mar 2017 Status changed from active, no longer recruiting to recruiting.
    • 12 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Nov 2018,as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top